An evidence-based review of the clinical use of sertraline in mood and anxiety disorders

International Clinical Psychopharmacology

Volumn 24, Issue 2, 2009, Pages 43-60

  Sheehan, David V ^a   Kamijima, Kunitoshi ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Anxiety disorders; Depression; Obsessive compulsive disorder; Panic; Posttraumatic stress disorder; Serotonin; Sertraline

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGITATION; ALZHEIMER DISEASE; BULIMIA; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; DYSTHYMIA; EVIDENCE BASED PRACTICE; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; LIBIDO; LONG TERM CARE; MAJOR DEPRESSION; MICTURITION DISORDER; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PANIC; PEDIATRICS; POPULATION; POSTTRAUMATIC STRESS DISORDER; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; RELAPSE; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SKIN MANIFESTATION; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT INDICATION; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; CHILD; DEPRESSION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MOOD DISORDERS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 63849301718     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282f4b616     Document Type: Review

References (144)

1. Åberg-Wistedt A, Agren H, Ekselius L, Bengtsson F, Akerblad AC (2000). Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 20:645-652.
2. Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, et al. (1993). Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8:197-202.
3. Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, et al. (2004). Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161:1642-1649.
4. Almeida OP, Waterreus A, Hankey GJ (2006). Preventing depression after stroke: results from a randomized placebo-controlled trial. J Clin Psychiatry 67:1104-1109.
5. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders-DSM-IV-TR, Fourth Edition. Washington: American Psychiatric Association.
6. Amore M, Jori MC, AMISERT Investigators (2001). Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 16:317-324.
7. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005). Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med 3:449-456.
8. Back SE, Brady KT, Sonne SC, Verduin ML (2006). Symptom improvement in co-occurring PTSD and alcohol dependence. J Nerv Ment Dis 194: 690-696. Erratum in: J Nerv Ment Dis (2006).
9. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW (2005). Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 66:94-99.
10. Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, Clary CM (2004). Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry 65:405-413.
11. Barbee JG (1998). Mixed symptoms and syndromes of anxiety and depression: diagnostic, prognostic, and etiologic issues. Ann Clin Psychiatry 10:15-29.
12. Bennie EH, Mullin JM, Martindale JJ (1995). A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56:229-237.
13. Bergeron R, Ravindran AV, Chaput Y, Goldner E, Swinson R, van Ameringen MA, et al. (2002). Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study. J Clin Psychopharmacol 22:148-154.
14. Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE (2001). Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179:23-30.
15. Boyer P, Danion JM, Bisserbe JC, Hotton JM, Troy S (1998). Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 13 (1 Pt 2):157-169.
16. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM (2000). Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 283:1837-1844.
17. Brady KT, Clary CM (2003). Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Compr Psychiatry 44:360-369.
18. Brady KT, Sonne S, Anton RF, Randall CL, Back SE, Simpson K (2005). Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 29:395-401.
19. Brawman-Mintzer O, Lydiard RB (1996). Generalized anxiety disorder: issues in epidemiology. J Clin Psychiatry 57 (Suppl 7):3-8.
20. Breslau N, Wilcox HC, Storr CL, Lucia VC, Anthony JC (2004). Trauma exposure and posttraumatic stress disorder: a study of youths in urban America. J Urban Health 81:530-544.
21. Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, et al. (2002). Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow- up of effectiveness and costs. J Affect Disord 68:317-330.
22. Buckley NA, McManus PR (2002). Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 325:1332-1333.
23. Camey RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, et al. (2004). Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 66:466-474.
24. Cheeta S, Schrfano F, Oyefeso A, Webb L, Ghodse AH (2004). Antidepressant- related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 184:41 -47.
25. Chouinard G (1992). Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies. Int Clin Psychopharmacol 7 (Suppl 2):37-41.
26. Connor KM, Davidson JR, Chung H, Yang R, Clary CM (2006). Multidimensional effects of sertraline in social anxiety disorder. Depress Anxiety 23:6-10.
27. Cook EH, Wagner KD, March JS, Biederman J, Landau P, Wolkow R, Messig M (2001). Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adoiesc Psychiatry 40:1175-1181.
28. Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T (2005). Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatrica Scandinavica 111:429-435.
29. Davidson J, Peaiistein T, Londborg P, Brady KT, Rothbaum B, Bell J, et al. (2001a). Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 158:1974-1981.
30. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ (2006). Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 26:259-267. Erratum in: J Clin Psychopharmacol 2006; 26:473, dosage error in text.
31. Davidson JR (2004). Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. Int Clin Psychopharmacol 19:85-87.
32. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM (2001b). Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 58: 485-492.
33. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 63:308-315.
34. Doogan DP, Caillard V (1992). Sertraline in the prevention of depression. Br J Psychiatry 160:217-222.
35. Doraiswamy PM, Krishnan KR, Oxman T, Jenkyn LR, Coffey DJ, Burt T, Clary CM (2003). Does antidepressant therapy improve cognition in elderly depressed patients? J Gerontol A Biol Sci Med Sci 58:M1137-M1144.
36. Edwards JG, Anderson I (1999). Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533.
37. Ekselius L, Von Knorring L, Eberhard G (1997). A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 12:323-331.
38. Fabre LF, Abuzzahab FS, Amin M, Claghom JL, Mendels J, Petrie WM, et al. (1995). Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38:592-602.
39. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME (2000). Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59:119-126.
40. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS (2002). Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 22:137-147.
41. Feiger AD, Flament MF, Boyer P, Gillespie JA (2003). Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies. Int Clin Psychopharmacol 18:203-210.
42. Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T (2004). A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 19:9-18.
43. Food and Drug Administration (2004). Labeling Change Request Letter for Antidepressant Medications. Rockville, MD, October 28, 2004. Available at: http://www.fda.gov/cder/drug/antidepressants/SSRIIabelChange.htm
44. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R (1997). A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 58:104-107.
45. Freeman EW, Rickels K, Sondheimer SJ, Polansky M (1999). Differential response to antidepressants in women with premenstrual syndrome/ premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 56:932-939.
46. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S (2004). Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 161: 343-351.
47. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2000). SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst Rev CD001851.
48. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. (2002). Sertraline treatment of major depression in patients with acute Ml or unstable angina. JAMA 288:701-709.
49. Goldstein BJ, Goodnick PJ (1998). Selective serotonin reuptake inhibitors in the treatment of affective disorders-Ill. Tolerability, safety and pharmaco- economics. J Psychopharmacol 12:S55-S87.
50. Goodnick PJ, Goldstein BJ (1998). Selective serotonin reuptake inhibitors in affective disorders-l. Basic pharmacology. J Psychopharmacol 12:S5-S20.
51. Goodnick PJ, Goldstein (1998). Selective serotonin reuptake inhibitors in affective disorders-ll. Efficacy and quality of life. J Psychopharmacology 13(3 Suppl B):21-54.
52. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, et al. (1995). A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10:57-65.
53. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L (2002). Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 100:1219-1229.
54. Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, Wold JE (2003). Exposure therapy and sertraline in social phobia: l-year follow-up of a randomised controlled trial. Br J Psychiatry 182:312-318.
55. Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, et al. (2000). Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 57:76-82.
56. Hoehn-Saric R, Schlaepfer TE, Greenberg BD, McLeod DR, Pearlson GD, Wong SH (2001). Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders. Psychiatry Res 108:89-100.
57. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ (1999). Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double- blind, placebo-controlled, crossover study. Arch Fam Med 8:328-332.
58. Kamijima K, Kuboki T, Kumano H, Burt T, Cohen G, Arano I, Hamasaki T (2005). A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 20:265-273.
59. Kamijima K, Burt T, Cohen G, Arano I, Hamasaki T (2006). A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int Clin Psychopharmacol 21:1-9.
60. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC (1995). Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 152:1368-1371.
61. Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, et al. (1998a). Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA 280:1665-1672.
62. Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ, Thase ME, Kocsis JH, et al. (1998b). The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 59:598-607.
63. Kent JM, Coplan JD, Gorman JM (1998). Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 44:812-824.
64. Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE (1998). Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry 55:801-808.
65. Khouzam HR, Ernes R, Gill T, Raroque R (2003). The antidepressant sertraline: a review of its uses in a range of psychiatric and medical conditions. Compr Ther 29:47-53.
66. Kocsis JH, Zisook S, Davidson J, Shelton R, Yonkers K, Hellerstein DJ, et al. (1997). Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. Am J Psychiatry 154: 390-395.
67. Kocsis JH, Schatzberg A, Rush AJ, Klein DN, Howland R, Gniwesch L, et al. (2002). Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 59:723-728.
68. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, et al. (2001). Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 65:27-36.
69. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D (2002). Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 159:88-95.
70. Kornstein SG, Pearlstein TB, Fayyad R, Farfel GM, Gillespie JA (2006). Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies. J Clin Psychiatry 67:1624-1632.
71. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al. (2001). Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286:2947-2955.
72. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, et al. (1999). Placebo-controlled, multicenter study of sertraline treatment for obsessive- compulsive disorder. J Clin Psychopharmacol 19:172-176.
73. Lepine JP, Goger J, Blashko C, Probst C, Moles MF, Kosolowski J, et al. (2000). A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. Int Clin Psychopharmacol 15:263-271.
74. Lepine JP, Caillard V, Bisserbe JC, Troy S, Hotton JM, Boyer P (2004). A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 161:836-842.
75. Lepola U, Arato M, Zhu Y, Austin C (2003). Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 64:654-662.
76. Liebowitz MR (1997). Panic disorder as a chronic illness. J Clin Psychiatry 58 (Suppl 13):5-8.
77. Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, et al. (2003). Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64:785-792.
78. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, et al. (1998). Sertraline in the treatment of panic disorder. A multi-site, double- blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173: 54-60.
79. Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmeihoch JM, Maddock R, et al. (2001). Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 62: 325-331.
80. Lowe B, Schenkel I, Bair MJ, Gobel C (2005). Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients. J Affect Disord 87:271-279.
81. Lundmark J, Nasman P, Olsson JE, Samuelsson M, Terent A, Varelius R, et al. (2005). Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J Clin Psychiatry 66:708-716.
82. Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, et al. (2006). Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 63:521-529.
83. Lydiard R, Perera P, Batzar E, Clary C (1999). From the bench to the trench: a comparison of sertraline treatment of major depression in clinical and research patient samples. Prim Care Companion J Clin Psychiatry 1:154-162.
84. Lydiard RB, Stahl SM, Hertzman M, Harrison WM (1997). A double-blind, placebo-controlled study comparing the effects of sertraline versus amitripty- line in the treatment of major depression. J Clin Psychiatry 58:484-491.
85. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, et al. (2003). Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60:737-746.
86. Macgillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F, et al. (2003). Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 326:1014-1017.
87. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC (1996). Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53:159-168.
88. March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280:1752-1756.
89. Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M (2005). A comparative trial of psychotherapy and pharmacotherapy for 'pure' dysthymic patients. J Affect Disord 89:167-175. Epub 2 November 2005.
90. McRae AL, Brady KT (2001). Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin Pharmacother 2:883-892.
91. Mehtonen OP, Sogaard J, Roponen P, Behnke K (2000). Randomized, double- blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 61: 95-100.
92. Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, Klimkeit E (2006). A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 45:1151-1161.
93. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner RG (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 176:363-368.
94. Murdoch D, McTavish D (1992). Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 44:604-624.
95. Newhouse PA, Krishnan KR, Doraiswamy PM, Richter EM, Batzar ED, Clary CM (2000). A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 61:559-568.
96. Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, et al. (2006). High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 67:15-22.
97. Oslin DW, Ten Have TR, Streim JE, Datto CJ, Weintraub D, DiFilippo S, Katz IR (2003). Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 64:875-882.
98. Otto MW, Hinton D, Korbly NB, Chea A, Ba P, Gershuny BS, Pollack MH (2003). Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behav Res Ther 41: 1271-1276.
99. O'Reardon JP, Allison KC, Martino NS, Lundgren JD, Heo M, Stunkard AJ (2006). A randomized, placebo-controlled trial of sertraline in the treatment of night eating syndrome. Am J Psychiatry 163:893-898.
100. Pediatric OCD Treatment Study (POTS) Team (2004). Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 292:1969-1976.
101. Pfizer Inc (2006). Zoloft Prescribing Information.
102. Pohl RB, Wolkow RM, Clary CM (1998). Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry 155:1189-1195.
103. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R (1998). Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 55:1010-1016.
104. Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R (2000). Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry 61:922-927.
105. Price JS, Waller PC, Wood SM, MacKay AV (1996). A comparison of the postmarketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 42:757-763.
106. Raj A (2004). Depression in the elderly. Tailoring medical therapy to their special needs. Postgrad Med 115:26-42.
107. Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C (2000). Is placebo response the same as drug response in panic disorder? Am J Psychiatry 157:1014-1016.
108. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2001). Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104:289-298.
109. Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P (2003). A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 44:216-221.
110. Ravindran AV, Anisman H, Merali Z, Charbonneau Y, Telner J, Bialik RJ, et al. (1999). Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments. Am J Psychiatry 156:1608-1617.
111. Ravindran AV, Guelfi JD, Lane RM, Cassano GB (2000). Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. J Clin Psychiatry 61:821-827.
112. Regier DA, Rae DS, Narrow WE, Kaelber CT, Schatzberg AF (1998). Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders. Br J Psychiatry Suppl 34:24-28.
113. Reimherr FW, Chouinard G, Conn CK, Cole JO, Itil TM, Lapierre YD, et al. (1990). Antidepressant efficacy of sertraline: a double-blind, placebo- and amitripty- line-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 51 (Suppl B): 18-27.
114. Robinson RG (1998). Prevalence of depressive disorders. In: Robinson RG, editor. The clinical neuropsychiatry of stroke: cognitive, behavioral, and emotional disorders following vascular brain injury, 1st ed, Cambridge, United Kingdom: Cambridge University Press; pp. 53-59.
115. Ronfeld RA, Tremaine LM, Wilner KD (1997). Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32 (Suppl 1):22-30.
116. Rossini D, Serretti A, Franchini L, Mandelli L, SmeraWi E, De Ronchi D, Zanardi R (2005). Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol 25:471-475.
117. Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, et al. (2006). Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 19:625-638.
118. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K (2003). An 8-week multicenter, parallel-group, double-blind, placebo- controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 160:1277-1285.
119. Schuurmans J, Comijs H, Emmelkamp PM, Gundy CM, Weijnen I, van den Hout M, van Dyck R (2006). A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry 14:255-263.
120. Sechter D, Troy S, Paternetti S, Boyer P (1999). A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 14:41-48.
121. Serebruany VL, Glassman AH, Malinin Al, Nemeroff CB, Musselman DL, van Zyl LT, et al. (2003). Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 108:939-944.
122. Sheikh Jl, Londborg P, Clary CM, Fayyad R (2000). The efficacy of sertraline in panic disorder: combined results from two fixed-dose studies. Int Clin Psychopharmacol 15:335-342.
123. Sheikh Jl, Cassidy EL, Doraiswamy PM, Salomon RM, Hornig M, Holland PJ, et al. (2004). Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J Am Geriatr Soc 52:86-92.
124. Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RM, et al. (2006). A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 67: 1674-1681.
125. Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. (2005). Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 66:1312-1320.
126. Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV (2006). A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 67: 1133-1139.
127. Stahl SM (2000). Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 48:894-901.
128. Steiner M, Allgulander C, Ravindran A, Kosar H, Burt T, Austin C (2005). Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. Hum Psychopharmacol 20:3-13.
129. Suri RA, Altshuler LL, Rasgon NL, Calcagno JL Frye MA, Gitlin MJ, et al. (2000). Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 61:942-946.
130. Swenson JR, O'Connor CM, Barton D, Van Zyl LT, Swedberg K, Forman LM, et al; Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group (2003). Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 92:1271-1276.
131. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, et al. (1996). A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 53:777-784.
132. Thase ME, Entsuah AR, Rudolph RL (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234-241.
133. Thiels C, Linden M, Grieger F, Leonard J (2005). Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. Int Clin Psychopharmacol 20:1-7.
134. van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. (2001). Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158:275-281.
135. Wagner KD, Cook EH, Chung H, Messig M (2003). Remission status after long- term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 13 (Suppl 1):S53-S60.
136. Walker JR, van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, et al. (2000). Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20:636-644.
137. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, et al. (2000). The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 55 (Suppl):5-10.
138. Whyte IM, Dawson AH, Buckley NA (2003). Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96:369-374.
139. Wilson KC, Mottram PG, Ashworth L, Abou-Saleh MT (2003). Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. Br J Psychiatry 182:492-497.
140. Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL (2004). Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry 161A 290-1292.
141. World Health Organization (2000). Information on depression, http:// www.who.int/mental-health/management/depression/definition/en/.
142. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, et al. (1997). Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 24:983-988.
143. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E (1996). Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153:1631-1633.
144. Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM, Austin C (2002). Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 22:190-195.